JEOL and SCiLS Sign a Distribution Agreement for SCiLS Lab MVS Software
TOKYO--(BUSINESS WIRE)--JEOL Ltd.(TOKYO:6951) (President & COO Izumi Oi) and SCiLS, a division of Bruker Daltonics,…
5 years ago
Enviro-Hub Expands Global Healthcare with FDA 510(k) certified medical-grade nitrile gloves
Environmental company recently acquired healthcare supply company Pastel Gloves as part of enhanced healthcare emphasis.…
5 years ago
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology…
5 years ago
Fabrinet to Present at Stifel Cross Sector Insight Conference
BANGKOK--(BUSINESS WIRE)--Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical…
5 years ago
MSD Animal Health to Acquire Assets of LIC Automation Ltd.
Automated Technology Enhances Dairy Farm Management Builds on Strong MSD Animal Health Commitment to New…
5 years ago
TikTok Influencer Marketing Platform, Clicks Talent, Announces Ambitious Plans for 2021
LOS ANGELES, June 07, 2021 (GLOBE NEWSWIRE) -- Leading TikTok influencer & marketing agency Clicks Talent…
5 years ago
Coupang Founder Bom Kim Joins CEOs of Starbucks, P&G, Mastercard, IBM, Cisco and Airbnb at FORTUNE Global Forum
SEOUL, South Korea--(BUSINESS WIRE)--Coupang today announced that founder and CEO Bom Kim will be a…
5 years ago
ProVen Growth and Income VCT plc: Annual Financial Report
PROVEN GROWTH AND INCOME VCT PLC ANNUAL FINANCIAL REPORTYEAR ENDED 28 FEBRUARY 2021 ProVen Growth…
5 years ago
ProVen VCT plc: Annual Financial Report
ProVen VCT plc Annual Financial ReportYear ended 28 February 2021 ProVen VCT plc, managed by…
5 years ago
Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma
-- CBM588 plus nivolumab/ipilimumab improved ORR and PFS compared to nivolumab/ipilimumab alone -- -- First…
5 years ago